scholarly journals Efficacy and safety of Chinese patent medicine (Jinlong capsule) in the treatment of advanced hepatocellular carcinoma: a meta-analysis

2020 ◽  
Vol 40 (1) ◽  
Author(s):  
He Xu ◽  
Wenjie Wei ◽  
Mu Y. ◽  
Chengwei Dong
Keyword(s):  
Hepatocellular Carcinoma ◽  
Conventional Treatment ◽  
Meta Analysis ◽  
Advanced Hepatocellular Carcinoma ◽  
Efficacy And Safety ◽  
Patient Response ◽  
Chinese Patent Medicine ◽  
Chinese Patent ◽  
Patent Medicine

Abstract Jinlong capsule (JLC), a type of herbal medicine, is considered to be a promising adjuvant therapy for hepatocellular carcinoma (HC). Although an analysis of the published literature has been performed, the exact effects and safety of JLC are yet to be systematically investigated. Therefore, a wide-ranging systematic search of electronic databases to draw conclusions was performed. Data from 29 trials, including 2488 patients with advanced HC, were analyzed. The results indicated that, compared with conventional treatment alone, the combination of conventional treatment and JLC markedly improved overall patient response (odds ratio (OR) 2.06 [95% confidence interval (CI) 1.71–2.49]; P<0.00001), disease control rate (DCR) (OR 2.17 [95% CI 1.74–2.71]; P<0.00001) and quality of life (QoL) (OR 2.71 [95% CI 2.05–3.58]; P<0.00001), and significantly prolonged 6- (P=0.01), 12- (P<0.00001), 24- (P=0.001) and 36-month (P<0.0001) overall survival (OS) rates. The immune function of patients was also significantly enhanced after combined conventional therapy and JLC treatment, indicated by clearly increased percentages of CD3+ (P<0.0001), CD4+ (P<0.00001) and natural killer (NK) cells (P=0.0003), and CD4+/CD8+ ratio (P<0.00001). The incidence of leukopenia (P<0.00001), hepatotoxicity (P=0.005), and myelosuppression (P=0.0007) was lower in HC patients injected with JLC, whereas other adverse events did not differ significantly between the two groups (P>0.05). In summary, results of this meta-analysis suggest that the combination of conventional treatment and JLC is more effective for the treatment of HC than conventional treatment alone.

scholarly journals Efficacy and Safety of the Chinese Patent Medicine Yuquan Pill on Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Sihan Peng ◽  
Ziyan Xie ◽  
Xiyu Zhang ◽  
Chunguang Xie ◽  
Jian Kang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Conventional Treatment ◽  
Efficacy And Safety ◽  
Chinese Patent Medicine ◽  
Chinese Patent ◽  
Treatment Of Diabetes ◽  
Patent Medicine

Background. Yuquan Pill (YQP), a Chinese patent medicine for the treatment of diabetes, is widely used in the treatment of diabetes and its complications in China. However, the efficacy of YQP on type 2 diabetes mellitus (T2DM) has not been completely assessed. The aim of this study is to evaluate the efficacy and safety of YQP in the treatment of T2DM. Materials and Methods. We systematically searched 9 databases for specific keywords from inception to Oct 2021. We included randomized controlled trials (RCTs) involving YQP in the treatment of T2DM without language limitation. The study conformed to the Cochrane Handbook and Review Manager software was used for data analysis. The weighted mean differences (WMDs) and 95% confidence intervals (CIs) were used to measure treatment effects. Results. The final analysis included 10 publications. Analysis showed that the combination of YQP and conventional treatment was more effective than conventional treatment alone with regard to the levels of fasting blood glucose (WMD = −0.83; 95% CI [−1.01,−0.66]; p < 0.00001 ), two-hour postprandial glucose (WMD = −1.40; 95% CI [−1.49,−1.31]; p < 0.00001 ), glycosylated hemoglobin (WMD = −0.87; 95% CI [−1.26, −0.49]; p < 0.00001 ), total cholesterol (WMD = −0.50; 95% CI [−0.61, −0.39]; p < 0.00001 ), c-reactive protein (WMD = −0.58; 95%CI [−0.88, −0.28]; p = 0.0002 ), and overall effective rate (RR = 1.21; 95% CI [1.12, 1.31]; p < 0.00001 ). Conclusion. Evidence suggested that YQP might improve glucose and lipid metabolism and inflammation in patients with T2DM. Serious adverse events were not reported. The quality of the evidence analyzed was low and therefore our results should be interpreted with caution. More high-quality RCTs are now needed to verify these findings.

Sign in / Sign up

Export Citation Format

Share Document